AR123174A1 - Agonistas del receptor npy2 solubles - Google Patents
Agonistas del receptor npy2 solublesInfo
- Publication number
- AR123174A1 AR123174A1 ARP210102204A ARP210102204A AR123174A1 AR 123174 A1 AR123174 A1 AR 123174A1 AR P210102204 A ARP210102204 A AR P210102204A AR P210102204 A ARP210102204 A AR P210102204A AR 123174 A1 AR123174 A1 AR 123174A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- gln
- glu
- ala
- leu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Análogos de PYY que tienen alanita en la posición 4, lisina en la posición 7, QRY como el extremo del terminal C y un grupo de prolongación de semivida. Los análogos son solubles a alrededor de pH 6 y 7. También composiciones farmacéuticas que comprenden tales análogos de PYY y al uso médico de los análogos. Reivindicación 1: Un análogo de PYY, caracterizado porque el análogo de PYY es un compuesto que tiene la fórmula: R¹-Z-R², en donde R¹ es hidrógeno, -C(O)C₁₋₆ alquilo, -C(O)C₆H₆, -C(O)C₃₋₆ cicloalquilo, -C(O)C₁₋₆ alquil-C₃₋₆ cicloalquilo, C₁₋₆ alquilo o C₁₋₆ alquil-C₃₋₆ cicloalquilo; R² es OH o NHR³, en donde R³ es hidrógeno o C₁₋₃ alquilo; y Z es un péptido que comprende una secuencia de aminoácidos de la fórmula Ib: Ala-Pro-X⁶-Lys-X⁸-X⁹-X¹⁰-X¹¹-X¹²-X¹³-X¹⁴-X¹⁵-X¹⁶-X¹⁷-Gln-X¹⁹-X²⁰-X²¹-X²²-X²³-Leu-Arg-His-X²⁷-X²⁸-X²⁹-X³⁰-Leu-X³²-X³³-Gln-Arg-Tyr (Ib) en donde X⁶ se selecciona del grupo que consiste en Ala y Glu; X⁸ se selecciona del grupo que consiste en Ala y Pro; X⁹ se selecciona del grupo que consiste en Glu, Gly y Pro; X¹⁰ se selecciona del grupo que consiste en Ala y Glu; X¹¹ se selecciona del grupo que consiste en Ala, Asp, Glu, Ile, Leu, Pro, Gln y Ser; X¹² se selecciona del grupo que consiste en Ala, Glu, Leu, Pro, Gln y Ser; X¹³ se selecciona del grupo que consiste en Ala, Glu, Leu, Ser, Gln, Thr y Pro; X¹⁴ se selecciona del grupo que consiste en Ala, Glu, Leu, Pro, Gln y Ser; X¹⁵ se selecciona del grupo que consiste en Ala y Glu; X¹⁶ se selecciona del grupo que consiste en Ala, Glu y Lys; X¹⁷ se selecciona del grupo que consiste en Ala, Glu, Ile, Leu, Pro, Gln, Ser, Thr y Val; X¹⁹ se selecciona del grupo que consiste en Ala, Glu, Leu, Arg, Lys, Pro, Ser y Gln; X²⁰ se selecciona del grupo que consiste en Gln y Tyr; X²¹ se selecciona del grupo que consiste en Gln y Tyr; X²² se selecciona del grupo que consiste en Ala, Glu, Ile, Leu, Pro, Gln, Ser, Thr y Val; X²³ se selecciona del grupo que consiste en Ala, Glu, Gly, Leu, Pro, Gln, Ser, Thr y Val; X²⁷ se selecciona del grupo que consiste en Gln y Tyr; X²⁸ se selecciona del grupo que consiste en Gln y Tyr; X²⁹ se selecciona del grupo que consiste en His, Asn y Gln; X³⁰ se selecciona del grupo que consiste en Trp y Lys; X³² se selecciona del grupo que consiste en Gln, Leu, Ser y Thr; y X³³ se selecciona del grupo que consiste en Lys y Arg; en donde de uno a tres aminoácidos de X⁵, X⁶, X⁸ - X¹⁹, X²¹ - X²⁴ y X²⁶ - X³² pueden estar ausentes, y en donde un grupo de prolongación de semivida está unido al grupo épsilon amino de la lisina en la posición 7, el grupo de prolongación de semivida consiste en un sustituyente lipófilo X y un ligador U, en donde el ligador U está unido a la cadena lateral de aminoácidos y X está unido a U, y el ligador U consiste en una, dos o tres subporciones (U¹, U², U³), en donde al menos una subporción es Ahx (ácido 6-aminohexanoico).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20189966 | 2020-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123174A1 true AR123174A1 (es) | 2022-11-02 |
Family
ID=71995807
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102204A AR123174A1 (es) | 2020-08-07 | 2021-08-06 | Agonistas del receptor npy2 solubles |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20220041678A1 (es) |
| EP (1) | EP4192853A1 (es) |
| JP (1) | JP2023537036A (es) |
| KR (1) | KR20230045088A (es) |
| CN (1) | CN116171282A (es) |
| AR (1) | AR123174A1 (es) |
| AU (1) | AU2021322137A1 (es) |
| BR (1) | BR112022025623A2 (es) |
| CA (1) | CA3185637A1 (es) |
| CL (1) | CL2023000357A1 (es) |
| CO (1) | CO2023000637A2 (es) |
| CR (1) | CR20230074A (es) |
| DO (1) | DOP2023000010A (es) |
| EC (1) | ECSP23003649A (es) |
| IL (1) | IL300239A (es) |
| MX (1) | MX2023001532A (es) |
| PE (1) | PE20231566A1 (es) |
| TW (1) | TW202222335A (es) |
| WO (1) | WO2022029231A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2022210988B9 (en) | 2021-01-20 | 2024-02-22 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| US20240091318A1 (en) | 2022-08-18 | 2024-03-21 | Boehringer Ingelheim International Gmbh | Combination therapy comprising long acting glp-1/glucagon and npy2 receptor agonists |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007525495A (ja) | 2004-02-11 | 2007-09-06 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 選択可能な特性を有するハイブリッドポリペプチド |
| BRPI0518559A2 (pt) | 2004-12-13 | 2008-11-25 | Amylin Pharmaceuticals Inc | motivos da famÍlia do polipetÍdeo pancreÁtico, polipeptÍdeos e mÉtodos compreendendo os mesmos |
| AU2008216265B2 (en) | 2007-02-15 | 2014-04-03 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| WO2008152403A1 (en) | 2007-06-15 | 2008-12-18 | Zealand Pharma A/S | Glucagon analogues |
| CN101939022A (zh) | 2007-11-14 | 2011-01-05 | 安米林药品公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
| WO2010070252A1 (en) | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| UA104605C2 (uk) | 2008-12-15 | 2014-02-25 | Зіленд Фарма А/С | Аналоги глюкагону |
| CN102282166B (zh) | 2008-12-15 | 2015-04-01 | 西兰制药公司 | 胰高血糖素类似物 |
| KR101593406B1 (ko) | 2008-12-15 | 2016-02-12 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| PL2454282T3 (pl) | 2009-07-13 | 2015-08-31 | Zealand Pharma As | Acylowane analogi glukagonu |
| EP2477643A1 (en) | 2009-09-18 | 2012-07-25 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| US20130096055A1 (en) | 2009-11-13 | 2013-04-18 | Novo Nordisk A/S | Long-acting y2 receptor agonists |
| UY33462A (es) | 2010-06-23 | 2012-01-31 | Zealand Pharma As | Analogos de glucagon |
| JP6023048B2 (ja) | 2010-06-24 | 2016-11-09 | ジーランド ファーマ アクティーゼルスカブ | グルカゴン類似体 |
| PL2718316T3 (pl) | 2011-06-10 | 2020-06-29 | Novo Nordisk A/S | Polipeptydy |
| KR20140114845A (ko) | 2011-12-23 | 2014-09-29 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| KR102184241B1 (ko) | 2012-05-03 | 2020-12-01 | 질랜드 파마 에이/에스 | Ｇｉｐ-ｇｌｐ-1 이원 작용제 화합물 및 방법 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| ES2732291T3 (es) | 2013-05-02 | 2019-11-21 | Glaxosmithkline Ip Dev Ltd | Péptidos terapéuticos |
| AR097701A1 (es) | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| EP3057984B1 (en) | 2013-10-17 | 2018-07-11 | Zealand Pharma A/S | Acylated glucagon analogues |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| TR201902516T4 (tr) | 2013-11-06 | 2019-03-21 | Zealand Pharma As | Glukagon-glp-1-gıp üçlü agonist bileşikleri. |
| MX2016006049A (es) | 2013-11-14 | 2016-08-12 | Keybioscience Ag | Mimeticos de calcitonina para tratar enfermedades y trastornos. |
| RS59026B1 (sr) | 2013-11-15 | 2019-08-30 | Novo Nordisk As | Selektivna pyy jedinjenja i njihova upotreba |
| JP6769984B2 (ja) | 2015-03-18 | 2020-10-14 | ジーランド ファーマ アクティーゼルスカブ | アミリン類似体 |
| MX2017012864A (es) | 2015-04-16 | 2018-06-12 | Zealand Pharma As | Analogo acilado del glucagon. |
| TWI694082B (zh) | 2015-06-12 | 2020-05-21 | 丹麥商諾佛 儂迪克股份有限公司 | 選擇性ｐｙｙ化合物及其用途 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| HRP20220995T1 (hr) | 2015-12-31 | 2022-11-11 | Hanmi Pharm. Co., Ltd. | Trostruki aktivator koji aktivira glukagonski, glp-1 i gip receptore |
| TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
| JOP20190097A1 (ar) | 2016-10-27 | 2019-04-28 | Janssen Pharmaceutica Nv | الجلوبولينات المناعية واستخداماتها |
| AR110300A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
| GB201704429D0 (en) | 2017-03-21 | 2017-05-03 | Keybioscience Ag | Calcitonin mimetics for treating diseases and disorders |
| TWI749381B (zh) | 2018-11-01 | 2021-12-11 | 美商美國禮來大藥廠 | 蛋白質酪胺酸-酪胺酸類似物及其使用方法 |
| JP2023500895A (ja) * | 2019-11-11 | 2023-01-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｎｐｙ２受容体アゴニスト |
-
2021
- 2021-08-05 KR KR1020237008139A patent/KR20230045088A/ko unknown
- 2021-08-05 CA CA3185637A patent/CA3185637A1/en active Pending
- 2021-08-05 PE PE2023000199A patent/PE20231566A1/es unknown
- 2021-08-05 CR CR20230074A patent/CR20230074A/es unknown
- 2021-08-05 BR BR112022025623A patent/BR112022025623A2/pt unknown
- 2021-08-05 IL IL300239A patent/IL300239A/en unknown
- 2021-08-05 MX MX2023001532A patent/MX2023001532A/es unknown
- 2021-08-05 AU AU2021322137A patent/AU2021322137A1/en active Pending
- 2021-08-05 CN CN202180057489.4A patent/CN116171282A/zh active Pending
- 2021-08-05 JP JP2023508079A patent/JP2023537036A/ja active Pending
- 2021-08-05 US US17/394,522 patent/US20220041678A1/en active Pending
- 2021-08-05 WO PCT/EP2021/071873 patent/WO2022029231A1/en active Application Filing
- 2021-08-05 EP EP21763019.3A patent/EP4192853A1/en active Pending
- 2021-08-06 TW TW110129087A patent/TW202222335A/zh unknown
- 2021-08-06 AR ARP210102204A patent/AR123174A1/es unknown
-
2023
- 2023-01-17 EC ECSENADI20233649A patent/ECSP23003649A/es unknown
- 2023-01-20 CO CONC2023/0000637A patent/CO2023000637A2/es unknown
- 2023-01-20 DO DO2023000010A patent/DOP2023000010A/es unknown
- 2023-02-03 CL CL2023000357A patent/CL2023000357A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023537036A (ja) | 2023-08-30 |
| AU2021322137A1 (en) | 2023-01-19 |
| WO2022029231A1 (en) | 2022-02-10 |
| CN116171282A (zh) | 2023-05-26 |
| MX2023001532A (es) | 2023-03-08 |
| US20220041678A1 (en) | 2022-02-10 |
| IL300239A (en) | 2023-03-01 |
| EP4192853A1 (en) | 2023-06-14 |
| CA3185637A1 (en) | 2022-02-10 |
| CO2023000637A2 (es) | 2023-01-26 |
| BR112022025623A2 (pt) | 2023-03-07 |
| ECSP23003649A (es) | 2023-03-31 |
| TW202222335A (zh) | 2022-06-16 |
| KR20230045088A (ko) | 2023-04-04 |
| DOP2023000010A (es) | 2023-02-15 |
| CL2023000357A1 (es) | 2023-09-29 |
| CR20230074A (es) | 2023-04-19 |
| PE20231566A1 (es) | 2023-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123174A1 (es) | Agonistas del receptor npy2 solubles | |
| JP7126270B2 (ja) | Ｎｐｒａアゴニスト、組成物およびその使用 | |
| JP2012530145A5 (es) | ||
| CZ287797A3 (cs) | Lipofilní deriváty peptidových hormonů | |
| JP6580581B2 (ja) | 注射用医薬組成物 | |
| KR20150126042A (ko) | 액체 수성 조성물 | |
| MX2014015028A (es) | Fragmentos o variantes de fibronectina modificada y usos de los mismos. | |
| JP2010523501A5 (es) | ||
| ECSP22037660A (es) | Agonistas del receptor npy2 | |
| CA3021231A1 (en) | Pegylated bioactive peptides and uses thereof | |
| JP2019520336A5 (es) | ||
| US20060166868A1 (en) | Vegf peptides and their use | |
| EP2911686B1 (en) | Peptides for preventing ischemic tissue injury | |
| EA044180B1 (ru) | Агонисты npra, композиции и их использование | |
| CA3104183A1 (en) | Synthetic peptides, prodrugs, pharmaceutical compositions and uses | |
| TW202026305A (zh) | 芋螺毒素(conotoxin)肽類似物及用於疼痛及發炎病症之治療的用途 | |
| CZ6764U1 (cs) | Peptldové analogy kuřecího GnRH II a lososího GnRH |